Immunotherapy for Alzheimer's disease: attacking amyloid-β from the inside

Trends in Immunology

Volumn 28, Issue 12, 2007, Pages 511-513

  Arbel, Michal ^a   Solomon, Beka ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; IMMUNOMODULATING AGENT;

ALZHEIMER DISEASE; CELL MEMBRANE; COGNITIVE DEFECT; DRUG MECHANISM; HIPPOCAMPUS; HUMAN; IMMUNOTHERAPY; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SENILE PLAQUE; SHORT SURVEY; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY;

EID: 36048998867     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2007.09.005     Document Type: Short Survey

References (19)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
2. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
3. Solomon B. Clinical immunologic approaches for the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs 16 (2007) 819-828
4. Billings L.M., et al. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 (2005) 675-688
5. Oddo S., et al. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 (2004) 321-332
6. Tampellini D., et al. Internalized antibodies to the Aβ domain of APP reduce neuronal Aβ and protect against synaptic alterations. J. Biol. Chem. 282 (2007) 18895-18906
7. Arbel M., et al. Inhibition of amyloid precursor protein processing by β-secretase through site-directed antibodies. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7718-7723
8. Oddo S., et al. A dynamic relationship between intracellular and extracellular pools of Aβ. Am. J. Pathol. 168 (2006) 184-194
9. Teller J.K., et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 2 (1996) 93-95
10. McLean C.A., et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
11. Gouras G.K., et al. Intraneuronal Aβ42 accumulation in human brain. Am. J. Pathol. 156 (2000) 15-20
12. Takahashi R.H., et al. Intraneuronal Alzheimer Aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161 (2002) 1869-1879
13. Laferla F.M., et al. Intracellular amyloid-β in Alzheimer's disease. Nat. Rev. Neurosci. 8 (2007) 499-509
14. Oddo S., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39 (2003) 409-421
15. Oakley H., et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26 (2006) 10129-10140
16. Solomon B., et al. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4109-4112
17. Schenk D., et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
18. Bard F., et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 (2000) 916-919
19. DeMattos R.B., et al. Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8850-8855